Prolastin
Links shared publicly online about this topic
Talecris Biotherapeutics Study Demonstrates PROLASTIN®-C Is As Effective As PROLASTIN®
medicalnewstoday.com — “Talecris Biotherapeutics (Nasdaq: TLCR) announced the publication of results from a study showing that PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN&r” View full resource at medicalnewstoday.com
Most Recently Shared on October 22, 2010 at 6:05 pm By:
MNT Gastrointestinal Health News
Talecris Biotherapeutics Study Demonstrates PROLASTIN®-C Is As Effective As PROLASTIN® http://mnt.to/3LCv #gastrointestinal
Talecris Biotherapeutics Receives FDA Approval for Prolastin-C
drugs.com — “Prolastin-C (Alpha1-Proteinase Inhibitor [Human]) is used to treat Alpha-1 Proteinase Inhibitor Deficiency. Includes Prolastin-C side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 19, 2009 at 11:25 pm By:
Talecris Biotherapeutics Receives FDA Approval for Prolastin-C - http://bit.ly/5wST9
Concentrated Prolastin-C approved for alpha1-antitrypsin (AAT) deficiency - MPR
empr.com — “The FDA has approved Prolastin-C (alpha1-proteinase inhibitor [human], from Talecris Biotherapeutics), a more concentrated formulation of Prolastin, for the treatment of alpha1-antitrypsin (AAT) deficiency.” View full resource at empr.com
Most Recently Shared on November 15, 2009 at 9:15 pm By:
Concentrated Prolastin-C approved for alpha1-antitrypsin (AAT) deficiency ... http://cli.gs/S678E
Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal
news-medical.net — “Talecris Biotherapeutics today announced the publication of results from a study showing that PROLASTIN-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 protein in patients with alpha1-antitrypsin (AAT) deficiency.” View full resource at news-medical.net
Most Recently Shared on October 22, 2010 at 9:34 am By:
Medicare News: Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal: Tale... http://bit.ly/9sPgSI
Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency
news-medical.net — “Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of d” View full resource at news-medical.net
Most Recently Shared on December 10, 2010 at 9:34 am By:
Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency: Talecr... http://bit.ly/ep6YlX
Talecris Biotherapeutics Launches PROLASTIN-C in Canada - Health News - redOrbit
redorbit.com — “RESEARCH TRIANGLE PARK, N.C., Nov.” View full resource at redorbit.com
Most Recently Shared on November 2, 2010 at 11:13 pm By:
Talecris Biotherapeutics Launches PROLASTIN®-C in Canada: RESEARCH TRIANGLE PARK, N.C., Nov. 2, 2010 /PRNewswire/ ... http://bit.ly/cJms0l
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MNT Gastrointestinal
The latest gastrointestinal news published daily. Articles from research centers, universities and prestigious journals.
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Bo
Internet Entrepreneur interested in health issues, co-founder of DrEveryone.com
Advertisement
